RxDoctor Payments Data

Lee Epstein, MD

Urogynecology and Reconstructive Pelvic Surgery · Jacksonville Beach, FLNPI 1174518401

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,550 of the $5,764 with a category attached, or 78.9%. Astellas Pharma US Inc accounts for 86.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $5,085 and has fallen 97.8% since, to $111 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in FL, where the typical reported total is $5,437.

$5,764in general payments, 2019–2025

Across 38 payments — averaging $151.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$5K
  • Coloplast$335
  • Escala Medical Inc.$168
  • Caldera Medical, Inc$64
  • Axonics, Inc.$45
  • Pfizer$34
  • plus $149 from 8 others

What the payments were for

  • Speaking & faculty fees$4,55079%
  • Food & beverage$1,21421%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,764 in reported general payments places this provider in the 50th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$287,153
Medicare patients
509
Services billed
2,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron243$178,883
GemtesaVibegron143$122,142
Mirabegron ErMirabegron19$12,768
Estradiol177$12,047
Trospium Chloride ErTrospium Chloride22$3,782
Solifenacin Succinate91$2,844
YuvafemEstradiol14$2,496
Fesoterodine Fumarate ErFesoterodine Fumarate11$1,080
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst39$785
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav100$718
NitrofurantoinNitrofurantoin Macrocrystal16$684
Clobetasol Propionate20$590
Amitriptyline Hcl32$563
LoperamideLoperamide Hcl25$523
Trospium Chloride12$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$4,969$178,883243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in Jacksonville Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →